Monday, December 3, 2001
Treatment of hypercholesterolemia largely involves diet, exercise, and
judicious use of statins, which inhibit intracellular cholesterol synthesis. But the
treatment regimens often do not bring patient cholesterol down to target levels.
Researchers now have identified a new class of compounds that appear to act downstream of
the statins and decrease circulating cholesterol in mice. However it is unclear if the new
compounds will be synergistic with or will antagonize the beneficial effects of statins.
Scientists from GlaxoSmithKline plc (GSK; LSE:GSK, London, U.K.) last
week published in Nature Medicine the identification of